Total costs of basal or premixed insulin treatment in 5077 insulin-naïve type 2 diabetes patients: register-based observational study in clinical practice

Table 2 Costs (SEK) of health care and treatments before and after starting the insulin treatment

	Pre-index		Post-index		Increment		Net cost effect
	Health care	Treatment	Health care	Treatment	Health care	Treatment	Net cost effect
Treatment	Mean/Median	Mean/Median	Mean/Median	Mean/Median	Mean/Median	Mean/Median	Mean/Median
NPH	19,674/3,228	2,455/1,587	16,570/3,240	8,191/6,840	−3,104/0	5,736/4,528	2,632/4,528
IG	22,861/3,457	2,857/1,959	19,746/3,143	10,818/9,343	−3,115/0	7,962/6,551	4,847/6,551
ID	9,544/2,458	3,041/1,608	11,402/2,647	12,351/10,706	1,858/0	9,310/7,690	11,168/7,690
PM	30,990/4,806	2,155/1,430	22,441/3,681	8,617/7,877	−8,549/-265	6,462/5,972	−2,087/5,707
p-values	<0.0001	<0.0001	0.0001	<0.0001	0.0011	<0.0001

NPH Neutral protamine Hagedorn, IG insulin glargine, ID insulin determir, PM premixed insulin, SD standard deviation. The approximate value of 100 SEK is currently 12 US dollars (August 2015)

ISSN: 2055-8260